A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2012
At a glance
- Drugs Semapimod (Primary)
- Indications Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Cytokine PharmaSciences
- 14 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2009 New trial record.